213 related articles for article (PubMed ID: 38532632)
21. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
Chen Z; Zhang W; Yan Z; Zhang M
Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
[TBL] [Abstract][Full Text] [Related]
22. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
23. Gene Signatures and Prognostic Values of m
Lu S; Yu Z; Xiao Z; Zhang Y
Front Oncol; 2020; 10():875. PubMed ID: 32596151
[TBL] [Abstract][Full Text] [Related]
24. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
25. m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma.
Ma T; Wang J; Liu X; Zhang W; Meng L; Zhang Y
Front Genet; 2022; 13():864549. PubMed ID: 35528542
[TBL] [Abstract][Full Text] [Related]
26. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
27. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
Xu H; Yin L; Xu Q; Xiang J; Xu R
Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
[TBL] [Abstract][Full Text] [Related]
28. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
Qi LW; Jia JH; Jiang CH; Hu JM
Front Genet; 2020; 11():614566. PubMed ID: 33519919
[TBL] [Abstract][Full Text] [Related]
29. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
30. High expression of WTAP is related to poor prognosis in nasopharyngeal carcinoma.
Tao CJ; Zhang P; Chen YY; Chen M
Neoplasma; 2023 Apr; 70(2):229-239. PubMed ID: 36964720
[TBL] [Abstract][Full Text] [Related]
31. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
Front Oncol; 2021; 11():714267. PubMed ID: 34604051
[TBL] [Abstract][Full Text] [Related]
32. N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS).
Zhou S; Hua R; Quan S
J Ovarian Res; 2023 Apr; 16(1):73. PubMed ID: 37046273
[TBL] [Abstract][Full Text] [Related]
33. Characterization of m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration in Ovarian Cancer.
Luo Y; Sun X; Xiong J
Front Cell Dev Biol; 2021; 9():794801. PubMed ID: 35087835
[No Abstract] [Full Text] [Related]
34. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
35. Characterization of m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia.
Han S; Qi J; Fang K; Wang H; Tang Y; Wu D; Han Y
Cancer Med; 2022 Mar; 11(5):1413-1426. PubMed ID: 35023630
[TBL] [Abstract][Full Text] [Related]
36. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
37. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
38. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
Ye W; Huang T
PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365
[TBL] [Abstract][Full Text] [Related]
39. Characterization of ligamentum flavum hypertrophy based on m6A RNA methylation modification and the immune microenvironment.
He Z; Zhu Z; Tang T; Guo P; Gao M; Li B; Nguyen TCT; Chen H; Liu X; Zhou Z; Liu S
Am J Transl Res; 2022; 14(12):8800-8827. PubMed ID: 36628248
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
